Published in J Natl Cancer Inst on October 01, 1971
Repetitive sequences in complete and defective genomes of Herpesvirus saimiri. J Virol (1975) 2.36
Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: evidence for a "hit and run" mechanism. Br J Exp Pathol (1976) 1.03
Solubilization and characterization of Herpesvirus saimiri-induced membrane antigens. J Virol (1978) 0.84
Stimulation of Herpesvirus saimiri expression in the absence of evidence for type C virus activation in a marmoset lymphoid cell line. J Virol (1974) 0.81
Endemic Viruses of Squirrel Monkeys (Saimiri spp.). Comp Med (2015) 0.75
Response to primary infection with Herpesvirus saimiri in immunosuppressed juvenile and newborn squirrel monkeys. Infect Immun (1975) 0.75
Effect of cytosine arabinoside, adenine arabinoside, tilorone, and rifamycin SV on multiplication of Herpesvirus saimiri in vitro. Antimicrob Agents Chemother (1972) 0.75
Microtissue culture plaque assay for Herpesvirus saimiri. Appl Microbiol (1973) 0.75
Virus induced lymphoproliferative disease in non-human primates. Br J Cancer Suppl (1975) 0.75
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science (1986) 8.15
A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med (1992) 3.42
Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. J Natl Cancer Inst (1969) 3.33
In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med (1988) 2.81
Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut (2003) 2.64
HBLV (or HHV-6) in human cell lines. Nature (1987) 2.53
Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta (1981) 2.51
Genomic analysis of the human B-lymphotropic virus (HBLV). Science (1986) 2.23
Strain MC29 avian leukosis virus. Myelocytoma, endothelioma, and renal growths: pathomorphological and ultrastructural aspects. J Natl Cancer Inst (1967) 2.08
Long-term feeding of sodium saccharin to nonhuman primates: implications for urinary tract cancer. J Natl Cancer Inst (1998) 2.04
Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog Horm Res (1988) 1.99
Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature (1989) 1.96
Transformation of human bronchial epithelial cells transfected by Harvey ras oncogene. Science (1985) 1.88
Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci U S A (1992) 1.85
Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg (2001) 1.63
Effects of long-term oral administration of DDT on nonhuman primates. J Cancer Res Clin Oncol (1999) 1.63
Quantitative fluorescence microscopy on single capillaries: alpha-lactalbumin transport. Am J Physiol (1987) 1.61
Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol (1998) 1.58
Species differences in the aromatization of quinic acid in vivo and the role of gut bacteria. Biochem J (1970) 1.51
Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer (1988) 1.51
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol (2001) 1.49
Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion (2003) 1.47
Clinical, epidemiologic, and virologic studies in four clusters of the chronic fatigue syndrome. Arch Intern Med (1992) 1.46
Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus materials. J Natl Cancer Inst (1975) 1.44
Requirement of Rac activity for maintenance of capillary endothelial barrier properties. Am J Physiol Heart Circ Physiol (2003) 1.41
Fine needle aspiration of palpable breast lumps: a 1-year audit using the Cytospin method. Cytopathology (1992) 1.39
Origin auxiliary sequences can facilitate initiation of simian virus 40 DNA replication in vitro as they do in vivo. Mol Cell Biol (1989) 1.37
Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients. Int J Cancer (1975) 1.35
Starling forces that oppose filtration after tissue oncotic pressure is increased. Am J Physiol Heart Circ Physiol (2000) 1.35
Toxicity of antineoplastic agents in man, chromosomal aberrations antifertility effects, congenital malformations, and carcinogenic potential. Adv Cancer Res (1975) 1.34
Antibody reactions to herpesvirus saimiri (HVS)-induced early and late antigens (EA and LA) in HVS-infected squirrel, marmoset and owl monkeys. Int J Cancer (1973) 1.34
Molecular studies of HHV-6. J Virol Methods (1988) 1.32
Response of bone marrow to MC29 avian leukosis virus in vitro. Cancer Res (1969) 1.30
The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res (1965) 1.29
Diverse tropism of HBLV (human herpesvirus 6) Lancet (1987) 1.29
Lobo's disease in an atlantic bottle-nosed dolphin. J Am Vet Med Assoc (1971) 1.26
Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer (1971) 1.25
Antitumor activity and other biologic properties of L-asparaginase (NSC-109229)-a review. Cancer Chemother Rep (1968) 1.25
The spectrum of clinical and laboratory findings resulting from human herpesvirus-6 (HHV-6) in patients with mononucleosis-like illnesses not resulting from Epstein-Barr virus or cytomegalovirus. Am J Clin Pathol (1990) 1.23
Human herpesvirus 7 (HHV-7) strain JI: independent confirmation of HHV-7. J Infect Dis (1992) 1.22
Embryotoxic effect of poly I. poly C. Nature (1969) 1.20
Endothelial glycocalyx: permeability barrier and mechanosensor. Ann Biomed Eng (2011) 1.19
Antigenic relationships among human herpesvirus-6 isolates. J Med Virol (1992) 1.18
Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst (1971) 1.17
Identification of the human herpesvirus 6 glycoprotein H and putative large tegument protein genes. J Virol (1991) 1.17
Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B cell lymphoma tissues of three patients. Leukemia (1988) 1.17
Preparation of immune rabbit sera with neutralizing activity against human cytomegalovirus and varicella-zoster virus. J Gen Virol (1970) 1.15
Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis (1994) 1.14
Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol (1999) 1.14
Ultramorphological and ultracytochemical studies on tubuloreticular structures in lymphoid cells. Cancer Res (1972) 1.14
Bovine plasma thromboplastin antecedent (Factor XI) deficiency. J Lab Clin Med (1969) 1.12
Development of procoagulant (tissue thromboplastin) activity in cultured leukocytes. J Lab Clin Med (1972) 1.12
Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol (1991) 1.11
Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul Toxicol Pharmacol (1994) 1.11
cAMP protects endothelial barrier functions by preventing Rac-1 inhibition. Am J Physiol Heart Circ Physiol (2004) 1.10
Modulatory effects of Epstein-Barr, herpes simplex, and human herpes-6 viral infections and coinfections on cytokine synthesis. A comparative study. J Immunol (1992) 1.09
Permeability of single capillaries to intermediate-sized colored solutes. Am J Physiol (1983) 1.08
HTLV-III infection of EBV-genome-positive B-lymphoid cells with or without detectable T4 antigens. Int J Cancer (1987) 1.07
Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol (1993) 1.06
HHV-6 reactivation in chronic fatigue syndrome. Lancet (1991) 1.06
A repeat sequence, GGGTTA, is shared by DNA of human herpesvirus 6 and Marek's disease virus. J Virol (1988) 1.05
Human herpesvirus 6 (HHV6) and chronic fatigue syndrome (CFS). Can Dis Wkly Rep (1991) 1.05
Regulation of actin dynamics is critical for endothelial barrier functions. Am J Physiol Heart Circ Physiol (2004) 1.05
Gastrointestinal helminth infections in feeder pigs. Am J Vet Res (1970) 1.04
Latent herpesvirus-6 in salivary and bronchial glands. Lancet (1990) 1.03
The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys. Cancer Res (1965) 1.02
Differentiation of cross-reacting simian cytomegalovirus strains by late 19S rabbit neutralizing antibodies. J Immunol (1969) 1.02
Metabolism of food-derived heterocyclic amines in nonhuman primates. Mutat Res (1997) 1.01
Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexiate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate. Biochem Biophys Res Commun (1975) 1.01
Tonic regulation of vascular permeability. Acta Physiol (Oxf) (2013) 1.01
Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression. J Virol (1994) 1.00
Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res (1978) 1.00
Nucleic acids of RNA tumor viruses: identification and ultrastructure. Virology (1975) 1.00
Malignant transformation of a recurrent vestibular schwannoma. J Clin Pathol (2004) 0.99
Antibody prevalence to HBLV (human herpesvirus-6, HHV-6) and suggestive pathogenicity in the general population and in patients with immune deficiency syndromes. J Virol Methods (1988) 0.99
Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA (1988) 0.98
Adenomyoepithelioma of the skin: a case report with immunohistochemical and ultrastructural observations. Histopathology (1997) 0.98
Human lymphocytes produce pro-opiomelanocortin gene-related transcripts. Effects of lymphotropic viruses. J Biol Chem (1988) 0.98
Maintaining updated DNA-based HLA assignments in the National Marrow Donor Program Bone Marrow Registry. Rev Immunogenet (2000) 0.98
Clinical pharmacology of ivermectin. J Am Vet Med Assoc (1986) 0.97
Renal neoplastic response to leukosis virus strains BAI A (avian myeloblastosis virus) and MC29. Cancer Res (1976) 0.97
Electron microscopy of single-stranded RNA from vesicular stomatitis virus. Virology (1974) 0.96
Test of a two-pathway model for small-solute exchange across the capillary wall. Am J Physiol (1998) 0.96
Serum sialic acid levels in lung cancer patients. Pharmacology (1976) 0.96
Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). Cancer Chemother Rep (1965) 0.95
Comparative biochemistry of drug metabolism by azo and nitro reductase. Proc Natl Acad Sci U S A (1965) 0.95
Diffuse esophageal leiomyomatosis with localized dense eosinophilic infiltration. Dis Esophagus (2002) 0.95
Role of adhesion and contraction in Rac 1-regulated endothelial barrier function in vivo and in vitro. Am J Physiol Heart Circ Physiol (2004) 0.94
Murine cytomegalovirus: induction of and sensitivity to interferon in vitro. Infect Immun (1975) 0.93
DNA from two Orgyia pseudotsugata baculoviruses: molecular weight determination by means of electron microscopy and restriction endonuclease analysis. Virology (1979) 0.93
Ultrastructural alterations in avian leukemia myeloblasts exposed to actinomycin D in vitro. Cancer Res (1966) 0.93
Characterization of regions of the Caenorhabditis elegans X chromosome containing vitellogenin genes. J Mol Biol (1986) 0.93
Cellular immunity in infectious mononucleosis. II. Specific reactivity to Epstein-Barr Virus antigens and correlation with clinical and hematologic parameters. J Immunol (1978) 0.92
Thrombin increases permeability only in venules exposed to inflammatory conditions. Am J Physiol Heart Circ Physiol (2003) 0.92
The distribution, excretion and metabolism of hydroxyurea-C14. J Pharmacol Exp Ther (1965) 0.92
Preparation of rabbit immune serum with neutralizing activity against a simian cytomegalovirus (SA6). J Immunol (1969) 0.92
Morphological studies on Herpesvirus saimiri in subhuman and human cell cultures. Cancer Res (1971) 0.92